2018 issue 2

Volume 34, issue 2

Case report

Rebound effect after S1P receptor modulator treatment in a patient with relapsing-remitting multiple sclerosis

Maciej Świat^1,2, Magdalena Targosz-Gajniak¹, Małgorzata Szymańska³, Olga Rezner¹

1. Department of Neurology, Regional Hospital Rybnik, Poland
2. Jan Dlugosz University in Czestochowa, Poland
3. Centrum Terapii SM i Chorób Zwyrodnieniowych

Farmakoterapia w Psychiatrii i Neurologii 2018, 34 (2), 139–142
Date of publication: 10-09-2018
DOI: http://dx.medra.org/10.17393/fpn.2018.07.002

Keywords: multiple sclerosis, sphingosine-phosphate receptor modulator, amiselimod

Abstract

We present a case report of severe steroid-refractory rebound disease activity after cessation of MT-1303 (amiselimod) treatment in a patient with relapsing-remitting multiple sclerosis (RRMS), which has not been described in the literature previously. MT-1303 is a novel selective sphingosine-phosphate receptor (S1P1) modulator that was discovered by the chemical modification of fingolimod with the aim of avoiding its heart rate-reducing effect.

Article in pdf format

Address for correspondence:
Małgorzata Szymańska
Centrum Terapii SM i Chorób Zwyrodnieniowych
ul. Załęska 9, 40-571 Katowice, Poland
email: mklecha@wp.pl